AIM: The aim of this study was to evaluate the anti-atherogenic outcomes of pioglitazone, a thiazolidinedione derivative, in type 2 diabetic patients. METHODS: Eight patients with poor diabetic control were treated with 15 mg of pioglitazone for 4 months. Blood samples were collected monthly, and the levels of fasting plasma glucose (FPG), HbA1c, and lipids, such as triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol, were measured. Other parameters, including immunorecative insulin (IRI), remnant-like particle-cholesterol (RLP-C), adiponectin, plasminogen activator inhibitor type 1 (PAI-1), tumor necrosis factor (TNF)- alpha , leptin, brain natriuretic peptide (BNP), and high-sensitivity (hs)-C-reactive protein (CRP), were examined at the beginning and end of the study. In addition, clinically adverse side-effects were evaluated. RESULTS: Treatment with pioglitazone significantly decreased the levels of HbA1c, FPG, the homeostasis model assessment of insulin resistance (HOMA-IR) index, RLP-C, PAI-1, TNF- alpha , and hs-CRP, but not the level, IRI, lipids, or leptin. In contrast, adverse side-effects, including body weight gain, liver dysfunction and edema, were not observed during this study. CONCLUSION: These results strongly suggested that treatment with pioglitazone has a greater clinical benefit for the prevention of atherosclerosis, including coronary heart diseases, without any adverse side-effects.
AIM: The aim of this study was to evaluate the anti-atherogenic outcomes of pioglitazone, a thiazolidinedione derivative, in type 2 diabeticpatients. METHODS: Eight patients with poor diabetic control were treated with 15 mg of pioglitazone for 4 months. Blood samples were collected monthly, and the levels of fasting plasma glucose (FPG), HbA1c, and lipids, such as triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol, were measured. Other parameters, including immunorecative insulin (IRI), remnant-like particle-cholesterol (RLP-C), adiponectin, plasminogen activator inhibitor type 1 (PAI-1), tumor necrosis factor (TNF)- alpha , leptin, brain natriuretic peptide (BNP), and high-sensitivity (hs)-C-reactive protein (CRP), were examined at the beginning and end of the study. In addition, clinically adverse side-effects were evaluated. RESULTS: Treatment with pioglitazone significantly decreased the levels of HbA1c, FPG, the homeostasis model assessment of insulin resistance (HOMA-IR) index, RLP-C, PAI-1, TNF- alpha , and hs-CRP, but not the level, IRI, lipids, or leptin. In contrast, adverse side-effects, including body weight gain, liver dysfunction and edema, were not observed during this study. CONCLUSION: These results strongly suggested that treatment with pioglitazone has a greater clinical benefit for the prevention of atherosclerosis, including coronary heart diseases, without any adverse side-effects.
Authors: David E Kemp; Faramarz Ismail-Beigi; Stephen J Ganocy; Carla Conroy; Keming Gao; Sarah Obral; Elizabeth Fein; Robert L Findling; Joseph R Calabrese Journal: J Affect Disord Date: 2011-07-22 Impact factor: 4.839
Authors: Igor Pomytkin; João P Costa-Nunes; Vladimir Kasatkin; Ekaterina Veniaminova; Anna Demchenko; Alexey Lyundup; Klaus-Peter Lesch; Eugene D Ponomarev; Tatyana Strekalova Journal: CNS Neurosci Ther Date: 2018-04-24 Impact factor: 5.243
Authors: Brandon H Cline; Joao P Costa-Nunes; Raymond Cespuglio; Natalyia Markova; Ana I Santos; Yury V Bukhman; Aslan Kubatiev; Harry W M Steinbusch; Klaus-Peter Lesch; Tatyana Strekalova Journal: Front Behav Neurosci Date: 2015-02-26 Impact factor: 3.558
Authors: Brandon H Cline; Harry W M Steinbusch; Dmitry Malin; Alexander V Revishchin; Galia V Pavlova; Raymond Cespuglio; Tatyana Strekalova Journal: BMC Neurosci Date: 2012-09-18 Impact factor: 3.288